Metastatic Melanoma Therapeutics Global Market Report 2025
상품코드:1824413
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
전이성 흑색종 치료제 시장 규모는 향후 수년간 급성장할 것으로 전망됩니다. 2029년에는 CAGR 12.1%로 성장할 전망이며, 146억 4,000만 달러로 성장이 예측됩니다. 예측 기간의 성장은 환자 풀의 확대, 연구개발 이니셔티브, 바이오마커의 동정, 규제당국의 승인 촉진, 신흥경제국으로 시장 확대 등에 기인하고 있습니다. 예측 기간 주요 동향으로는 면역 요법의 병용, 정밀의료의 진보, 새로운 표적 요법, 수술 후의 보조 요법, 이중 특이성 항체의 개발 등이 있습니다.
향후 5년간의 성장률 12.1%라고 하는 예측은 전회 예측으로부터 0.1%라고 하는 미감소를 반영하고 있습니다. 이 감소는 주로 미국과 타국가 간 관세의 영향 때문입니다. 관세의 부과는 영국이나 싱가포르에서 수입되는 PD-1 체크포인트 억제제나 BRAF/MEK 억제제 병용요법의 비용을 상승시킴으로써 미국의 면역 요법에 대한 접근을 혼란시켜 생존예후를 해치고 흑색종의 치료비를 상승시킬 가능성이 있습니다. 또한 상호관세와 무역 긴장 증가 및 제한 증가로 인한 세계경제와 무역에 대한 악영향으로 그 영향이 더욱 광범위해질 것으로 보입니다.
전이성 흑색종 치료제 시장의 예상 성장은 두 가지 중요한 요인에 의해 촉진될 것으로 예측됩니다. 첫째, 흑색종의 이환율 상승이 시장 확대에 기여할 전망입니다. 흑색종은 피부의 색소 조절 세포인 멜라노사이트에서 발생하는 피부암의 일종으로 피부의 어느 곳에서나 발생할 수 있습니다. 전이성 흑색종 치료제는 돌연변이 화학물질을 차단하고 건강한 조직에 대한 해를 최소화하면서 흑색종 세포의 증식을 억제하도록 고안된 다양한 치료법을 포함합니다. 미국암협회에 따르면 2023년 미국에서 새롭게 진단되는 흑색종의 증례 수는 남성에서 58,120례, 여성에서 39,490례, 합계 약 97,610례로 약 7,990명이 사망한 것으로 평가되었습니다. 흑색종의 이환율 증가는 전이성 흑색종 치료제 시장 성장의 주요 촉진요인입니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향 및 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석 및 전략 분석 프레임워크
세계의 전이성 흑색종 치료제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인 및 억제요인)
최종 이용 산업의 분석
세계의 전이성 흑색종 치료제 시장 : 성장률 분석
세계의 전이성 흑색종 치료제 시장 실적 : 규모 및 성장(2019-2024년)
세계의 전이성 흑색종 치료제 시장 예측 : 규모 및 성장(2024-2029년, 2034년)
세계의 전이성 흑색종 치료제 : 총 잠재 시장 규모(TAM)
제6장 시장 세분화
세계의 전이성 흑색종 치료제 시장 : 치료별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
화학 요법
면역 요법
표적 요법
방사선 치료
수술
세계의 전이성 흑색종 치료제 시장 : 스테이지별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
스테이지 0
스테이지 I
스테이지 II
스테이지 III
스테이지 IV
세계의 전이성 흑색종 치료제 시장 : 최종 사용자별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
재택 헬스케어
기타 최종 사용자
세계의 전이성 흑색종 치료제 시장 : 화학요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
다카르바진
테모졸로미드
카르보플라틴 및 시스플라틴의 병용
세계의 전이성 흑색종 치료제 시장 : 면역 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
체크포인트 억제제
인터루킨-2(IL-2)
종양 용해성 바이러스 요법
세계의 전이성 흑색종 치료제 시장 : 표적 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
BRAF 억제제
MEK 억제제
KIT 억제제
세계의 전이성 흑색종 치료제 시장 : 방사선 요법 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
정위 방사선 수술
완화 방사선 요법
세계의 전이성 흑색종 치료제 시장 : 수술 유형별 세분화 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
종양 절제
센티넬 림프절 생검
종양 제거 수술
제7장 지역별 및 국가별 분석
세계의 전이성 흑색종 치료제 시장 : 지역별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
세계의 전이성 흑색종 치료제 시장 : 국가별 분석 및 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도 및 기업 프로파일
전이성 흑색종 치료제 시장 : 경쟁 구도
전이성 흑색종 치료제 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Bristol-Myers Squibb Company
AstraZeneca PLC
GlaxoSmithKline PLC
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Amgen Inc.
Regeneron Pharmaceuticals Inc.
Daiichi Sankyo Company Ltd.
Eisai Co. Ltd.
Incyte Corporation
Exelixis Inc.
BeiGene Ltd
Immunocore Holdings plc
Genentech Inc.
Iovance Biotherapeutics Inc.
제32장 세계 시장 경쟁 벤치마킹 및 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문 및 전략
전이성 흑색종 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
전이성 흑색종 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
전이성 흑색종 치료제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
AJY
영문 목차
영문목차
Metastatic melanoma therapeutics encompass a range of treatment options available for individuals diagnosed with metastatic melanoma, a type of skin cancer that has spread to other parts of the body. Melanoma arises from the transformation of pigmented cells called melanocytes, leading to the formation of tumors.
The primary types of metastatic melanoma therapeutics include chemotherapy, immunotherapy, targeted therapy, radiation therapy, and surgery. Chemotherapy involves the use of potent chemicals to eliminate rapidly proliferating cells in the body. The treatment may be administered at various stages, including stage 0, stage I, stage II, stage III, and stage IV, depending on the extent of the cancer. These therapeutic options are utilized by various healthcare providers, including hospitals, specialty clinics, home healthcare, and other medical facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The metastatic melanoma therapeutics market research report is one of a series of new reports from The Business Research Company that provides metastatic melanoma therapeutics market statistics, including metastatic melanoma therapeutics industry global market size, regional shares, competitors with a metastatic melanoma therapeutics market share, detailed metastatic melanoma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the metastatic melanoma therapeutics industry. This metastatic melanoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The metastatic melanoma therapeutics market size has grown rapidly in recent years. It will grow from $8.28 billion in 2024 to $9.29 billion in 2025 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to pioneering immunotherapy approval, targeted therapy innovations, clinical trial successes, introduction of combination therapies, advancements in diagnostic technologies.
The metastatic melanoma therapeutics market size is expected to see rapid growth in the next few years. It will grow to $14.64 billion in 2029 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to expanding patient pool, research and development initiatives, biomarker identification, accelerated regulatory approvals, market expansion into emerging economies. Major trends in the forecast period include immunotherapy combinations, precision medicine advances, emerging targeted therapies, adjuvant therapies after surgery, development of bi-specific antibodies.
The forecast of 12.1% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. immunotherapy access by increasing costs for PD-1 checkpoint inhibitors and BRAF/MEK inhibitor combinations imported from the UK and Singapore, potentially compromising survival outcomes and raising melanoma treatment costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The anticipated growth in the metastatic melanoma therapeutics market is expected to be propelled by two significant factors. Firstly, the rising incidence of melanoma cases is poised to contribute to market expansion. Melanoma, a form of skin cancer originating in melanocytes, the pigment-regulating cells in the skin, can occur anywhere on the skin. Metastatic melanoma therapeutics encompass various treatments designed to block mutant chemicals and impede the growth of melanoma cells while minimizing harm to healthy tissue. According to the American Cancer Society, it is estimated that there will be 58,120 new cases of melanomas diagnosed in males and 39,490 in females in the US in 2023, totaling around 97,610 cases, with approximately 7,990 predicted deaths. The rising incidence of melanoma is a key driver for the growth of the metastatic melanoma therapeutics market.
The growing demand for biologics is expected to further propel market growth. Biologics, therapeutic products derived from living organisms or containing components of living organisms, have transformed the treatment landscape for metastatic melanoma. They offer targeted and immunotherapy-based approaches that have significantly improved patient outcomes with minimal side effects compared to traditional chemotherapy. For instance, according to the US Food and Drug Administration reported that by the end of 2022, 40 biosimilars had received approval, with 27 of them available in the United States, providing alternatives to 10 brand-name biologics. The growing demand for biologics, with their targeted and immunotherapy benefits, is a significant driver for the metastatic melanoma therapeutics market.
The metastatic melanoma therapeutics market is currently witnessing a significant trend towards product innovations, with companies strategically leveraging recent technologies to enhance their market standing. Notably, in January 2022, UK-based biotechnology firm Immunocore obtained FDA approval for KIMMTRAK, the first-ever FDA-approved T cell receptor (TCR) therapy designed for treating unresectable or metastatic uveal melanoma. Developed using Immunocore's ImmTAC technology platform, KIMMTRAK demonstrated a noteworthy overall survival (OS) advantage, boasting a hazard ratio of 0.51 and a median OS of nearly 22 months.
Leading companies in the metastatic melanoma therapeutics sector are actively engaging in strategic collaborations to assess treatments for metastatic cutaneous melanoma. An example of this is the collaboration between Immunocore and Sanofi, announced in June 2022. The partnership involves a clinical trial collaboration and supply agreement, wherein Sanofi will evaluate its engineered IL-2, SAR444245, in combination with Immunocore's KIMMTRAK in patients with advanced unresectable or metastatic skin cancers.
In April 2022, Germany-based investment firm EMZ Partners acquired a majority stake in FotoFinder Systems GmbH, a move undisclosed in terms of financial details. This strategic partnership aims to facilitate FotoFinder Systems GmbH's expansion of its product portfolio and market reach. FotoFinder Systems GmbH specializes in providing skin visualization equipment utilized in melanoma therapeutics.
Major companies operating in the metastatic melanoma therapeutics market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Ltd., Eisai Co. Ltd., Incyte Corporation, Exelixis Inc., BeiGene Ltd, Immunocore Holdings plc, Genentech Inc., Iovance Biotherapeutics Inc., Nektar Therapeutics, Adaptimmune Therapeutics plc, AIVITA Biomedical Inc., Idera Pharmaceuticals Inc., Evaxion Biotech A/S, AB Science, AgonOX Inc., InxMed Co. Ltd., NewLink Genetics Corporation, Vical Inc.
North America was the largest region in the metastatic melanoma therapeutics market in 2024. The regions covered in the metastatic melanoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the metastatic melanoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The metastatic melanoma therapeutics market consists of sales of surgical resection, lymph node dissection, and lymphatic mapping and sentinel lymph node biopsy. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic melanoma therapeutics market also includes sales of trametinib (Mekinist), cobimetinib (Cotellic), and binimetinib (Mektovi). Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Metastatic Melanoma Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on metastatic melanoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for metastatic melanoma therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The metastatic melanoma therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Therapy: Chemotherapy; Immunotherapy; Targeted Therapy; Radiation Therapy; Surgery
2) By Stages: Stage 0; Stage I; Stage II; Stage III; Stage IV
3) By End User: Hospitals; Specialty Clinics; Home Healthcare; Other End-Users
Subsegments:
1) By Chemotherapy: Dacarbazine; Temozolomide; Carboplatin And Cisplatin Combinations
2) By Immunotherapy: Checkpoint Inhibitors; Interleukin-2 (IL-2); Oncolytic Virus Therapies
3) By Targeted Therapy: BRAF Inhibitors; MEK Inhibitors; KIT Inhibitors
4) By Radiation Therapy: Stereotactic Radiosurgery; Palliative Radiation Therapy
5) By Surgery: Tumor Resection; Sentinel Lymph Node Biopsy; Debulking Surgery
3. Metastatic Melanoma Therapeutics Market Trends And Strategies
4. Metastatic Melanoma Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Metastatic Melanoma Therapeutics Growth Analysis And Strategic Analysis Framework
5.1. Global Metastatic Melanoma Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Metastatic Melanoma Therapeutics Market Growth Rate Analysis
5.4. Global Metastatic Melanoma Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Metastatic Melanoma Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Metastatic Melanoma Therapeutics Total Addressable Market (TAM)
6.1. Global Metastatic Melanoma Therapeutics Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Surgery
6.2. Global Metastatic Melanoma Therapeutics Market, Segmentation By Stages, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Stage 0
Stage I
Stage II
Stage III
Stage IV
6.3. Global Metastatic Melanoma Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Home Healthcare
Other End-Users
6.4. Global Metastatic Melanoma Therapeutics Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dacarbazine
Temozolomide
Carboplatin And Cisplatin Combinations
6.5. Global Metastatic Melanoma Therapeutics Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Checkpoint Inhibitors
Interleukin-2 (IL-2)
Oncolytic Virus Therapies
6.6. Global Metastatic Melanoma Therapeutics Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
BRAF Inhibitors
MEK Inhibitors
KIT Inhibitors
6.7. Global Metastatic Melanoma Therapeutics Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Stereotactic Radiosurgery
Palliative Radiation Therapy
6.8. Global Metastatic Melanoma Therapeutics Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tumor Resection
Sentinel Lymph Node Biopsy
Debulking Surgery
7. Metastatic Melanoma Therapeutics Market Regional And Country Analysis
7.1. Global Metastatic Melanoma Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Metastatic Melanoma Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
